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Introduction: Multimodality treatment has achieved significant suc-
cess in local control and treatment of early-stage malignant pleural
mesothelioma patients. However, its favorable effect on survival is
questionable.
Methods: We have instituted a trimodality treatment protocol con-
sisting of extrapleural pneumonectomy, adjuvant high-dose (54 Gy)
hemithoracic irradiation, and platin-based chemotherapy in a multi-
institutional setting. Preoperative pulmonary function tests, echocar-
diogram, chest computed tomography, and magnetic resonance
imaging scans were performed in all patients. Twenty patients have
been treated with this protocol during 2003–2007. Seventeen had a
history of environmental asbestos/erionite exposure. Clinical stages
were T1-3N0-2.
Results: Median age was 56 (41–70, 8 female). There was one
postoperative mortality (% 5) due to ARDS. Morbidity occurred in
11 patients (% 55). Histology was epithelial in 17, mixed in 2, and
sarcomatoid in 1. Sixteen patients underwent extrapleural pneumo-
nectomy. Microscopic margin positivity was present in 14 patients
with macroscopic complete resection. Twelve patients completed all
three treatments. Median follow-up was 16 months (1–43). Overall
median survival was 17 months (24% at 2 years). Eight patients had
extrapleural lymph node involvement (internal mammary [n  3],
subcarinal [n 2], pulmonary ligament [n 1], diaphragmatic [n 1],
subaortic [n  1]). There was better survival in patients without
lymph node metastasis (24 versus 13 months median survival, p 
0.052). Currently, 7 patients are alive, 6 without recurrence, and 2
patients at 40 and 45 months.
Conclusions: Trimodality treatment in malignant pleural mesothe-
lioma seems to prolong survival in patients without lymph node
metastasis. Novel techniques are needed for preoperative assessment
of extrapleural lymph nodes.
Key Words: Malignant pleural mesothelioma, Extrapleural pneumo-
nectomy, High-dose hemithoracic irradiation, Adjuvant chemotherapy.
(J Thorac Oncol. 2008;3: 499–504)
Optimal treatment for malignant pleural mesothelioma(MPM) is still under investigation. Several treatment
strategies have been used with very limited success. Recent
studies have shown that some patients benefit from multimo-
dality treatment including aggressive surgery, radiation, and
chemotherapy.1–3 The multimodality treatment protocols
have achieved a median survival of 19 to 46 months depend-
ing on the stage, histology, and completeness of the surgical
resection.1–5 In a certain subgroup of patients with epithelial
histology, no lymph node involvement and complete surgical
resection the results were even more favorable with occa-
sional long-term survival.1
During the evolution of the treatment of MPM, successful
local control of the disease with acceptable morbidity and
mortality has been achieved through extrapleural pneumonec-
tomy (EPP) and adjuvant high-dose hemithoracic irradiation.2,3,6
The feasibility of high-dose hemithoracic irradiation following
EPP was investigated in a phase II trial from Memorial Sloan
Kettering Cancer center with local control rates over 90%.2,6 In
a similar study from MD Anderson Cancer center, despite
successful local control, distant recurrence, especially in the
abdomen, was a major problem in long term.7
We designed a protocol to test the feasibility of EPP,
followed by adjuvant high-dose irradiation and cisplatin-based
chemotherapy. This protocol was designed to achieve a low
local and distant recurrence rate and thus prolong survival.
MATERIALS AND METHODS
Study Design
The study was performed during 2003–2007. All pa-
tients with a histologically proven MPM were enrolled. The
protocol was approved by the faculty ethical council. The
protocol schema is depicted in Figure 1.
Pretreatment Assessment
The patients underwent radiologic evaluation including
chest and upper abdominal computed tomography scans,
thoracic magnetic resonance imaging, and positron emission
tomography scan after 2004. Brain or bone scanning was not
routinely performed. Cardiac evaluation included electrocar-
*Marmara University Hospital, Department of Thoracic Surgery, Istanbul,
Turkey; †Osmangazi University, Department of Pulmonary Medicine,
Eskisehir, Turkey; and ‡Marmara University, Department of Radiation
Oncology, Istanbul, Turkey.
Disclosure: The authors declare no conflicts of interest.
Address for correspondence: Hasan Fevzi Batirel, MD, PhD, Associate
Professor, Department of Thoracic Surgery, Marmara University Hospi-
tal, Tophanelioglu Cad. No: 13-15, Altunizade, Istanbul, Turkey 34662.
E-mail: hbatirel@marmara.edu.tr
Copyright © 2008 by the International Association for the Study of Lung
Cancer
ISSN: 1556-0864/08/0305-0499
Journal of Thoracic Oncology • Volume 3, Number 5, May 2008 499
diogram and echocardiography. Patients with ejection frac-
tions less than 45% were excluded. Pulmonary evaluation
included spirometry and ventilation-perfusion scintigraphy in
patients with FEV1 60%.
Surgery
All patients underwent general anesthesia and double
lumen intubation with an intention to perform EPP. A pos-
terolateral thoracotomy was performed with removal of the
6th rib. Resectability was assessed with extrapleural dissec-
tion. EPP was performed with en-bloc removal of the pleura,
ipsilateral lung, diaphragm, and pericardium in all patients
without gross chest wall or intrathoracic other organ invasion.
After removal of the specimen, the pleural cavity was
scrubbed three times with povidone-iodine sponges and irri-
gated with sterile water and saline. Diaphragm was recon-
structed using 2 mm PTFE or polyprolene mesh. Pericardium
was reconstructed with vicryl or vicryl-polyprolene compos-
ite mesh. The chest wound was closed accordingly with a single
28 Fr chest drain. Patients were extubated in the operating room
and kept in ICU typically for 2 days. The chest drain was
removed 48 to 72 hours postoperatively.
Pathology Protocol
All EPP specimens were sampled at 20 different sites
including costodiaphragmatic sulci, pericardium, lateral tho-
racic wall, apical, and mediastinal pleural margin. If all samples
did not show any tumor invasion beyond surgical margins, the
outcome was defined as a microscopic complete resection.
Otherwise, it was accepted as a macroscopic complete resection
with positive microscopic margins.
Hemithoracic Irradiation Protocol8
Adjuvant radiotherapy was delivered using photons by
a dual energy (6 and 18-mV) linear accelerator. A minimum
total dose of photons fields of 54 Gy (1.8Gy/fraction, 1 frac-
tion/d, 5 d/wk) was delivered to the hemithorax, the thoracotomy
incision, and sites of chest drains. A boost dose of 9 Gy was
considered for patients who had residual disease marked by
surgical clips with photon fields. The radiotherapy planning
ensures the coverage of the entire ipsilateral thoracic cavity from
the apex to the diaphragm, ipsilateral mediastinum, and surgical
incisions and all scars. The treatment technique consisted of two
opposed fields with custom blocks for each field, AP-PA, to the
whole hemithorax, shielding organs at risk. The organs at risk
were defined as spinal cord, kidneys, and liver (for right-sided
tumors). All of the treatment plans were done with computed
tomography based planning system with adequate dose volume
distribution for the target volumes and organs at risk.
Adjuvant Chemotherapy
Adjuvant chemotherapy was given as cisplatin and gem-
citabine in 2003–2005. The regimen was changed to cisplatin
and pemetrexed since 2005. In the first regimen, cisplatin was
given 75 mg/m2/d iv on day 1, gemcitabine 1250 mg/m2 iv on
days 1 and 8. In the second regimen, cisplatin was given 75
mg/m2 on day 1 iv, pemeterexed 500 mg/m2 iv on day 1.
Chemotherapy cycles were repeated every 21 days. The patients
typically received three cycles of chemotherapy. Cisplatin was
administered in 500 mL of normal saline over 2 hours (with
precisplatin and postcisplatin hydration and antiemetics). To
prevent nephrotoxicity, precisplatin and postcisplatin hydration
and diuresis were carried out by administering 1 L of normal
dextrose over 2 hours, furosemide with each liter of dextrose and
10% mannitol. Emesis was prevented with ondansetron or a
combination of metoclopramide and dexamethasone. Gemcitab-
ine was administered over 10 minutes in 100 mL dextrose/
saline. In patients who were scheduled to receive pemetrexed,
vitamin D and dexamethasone was administered 10 days before
the cycle.
Before each cycle, the patients underwent a complete
physical examination, chest radiograph, ECG, respiratory func-
tion tests, complete blood count, serum biochemistry, and urine
analysis. In addition, patients were screened for side effects on
7th and 14th days of the drug administrations. The side effects
were graded according to the WHO toxicity scale.9
Statistical Analysis
The study was designed to enroll 20 patients. Overall
survival was calculated using Kaplan-Meier method. Survival
differences were analyzed with log-rank test. Postoperative/
in-hospital deaths were included in the survival analysis.
RESULTS
Demographics
From 2003 to 2007, 37 patients were evaluated in our
clinic for multimodality treatment of mesothelioma. Twenty
patients were enrolled to the protocol. Median age was 56
(41–70) Patient characteristics are depicted in Table 1.
Eleven patients had a history of smoking.
FIGURE 1. The study protocol.
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Surgical Results
EPP could not be performed in 4 patients. In 2 patients
(one with epithelial and other with sarcomatoid MPM) tumor
was found to be unresectable because of diffuse chest wall
invasion. One patient was noticed to have diffuse millimetric
nodular implants within the intercostal muscles. Other patient
did not tolerate single lung ventilation. Both patients under-
went partial pleurectomy to achieve pleurodesis. Sixteen
patients underwent EPP (8 right and 8 left). There was 1 (5%)
in-hospital mortality. The patient had a ruptured diaphrag-
matic mesh, was re-explored and subsequently developed
ARDS and sepsis. Eleven (55%) patients developed compli-
cations, all in patients who underwent EPP. Six patients
developed supraventricular tachycardia. Five patients were
reexplored, 3 because of postoperative bleeding, 1 because of
diaphragmatic rupture, and 1 because of unexplained su-
praventricular tachycardia. Recurrent laryngeal nerve injury
(n  1), bronchopleural fistula (n  1), and hypoxic brain
damage (n  1) were among other major complications.
Pathology
The histologic subtype was epithelial in 17, sarcomatoid
in 2, and mixed in 1 patient. Only 2 patients who underwent EPP
were found to have microscopic complete resection. Micro-
scopic tumor positivity was present in 14 patients at apical
pleura (n  8), lateral chest wall (n  7), mediastinal pleura
(n  3), costodiaphragmatic sulci (n  3), and pericardium
(n  2).
Radiotherapy
Out of 16 patients who received EPP, 12 patients under-
went postoperative high-dose RT. Adjuvant radiation was not
administered to three patients who had postoperative complica-
tions and one patient who had abdominal relapse before the
initiation of radiotherapy. The median total dose given was 54
Gy (52–63 Gy). Overall treatment was well tolerated, with mild
dysphagia, fatigue, loss of appetite, nausea, and vomiting with-
out any treatment interruptions.
Chemotherapy Adverse Events
All 12 patients who completed multimodality therapy
were assessable for toxicity. The toxicity of these drug combi-
nations was mild and well-tolerated. There were no chemo-
therapy-related deaths. Myelosupression, which was the most
frequent adverse event (12% of all cycles), was mostly mild-to-
moderate, occurring mostly after the third cycle. In the begin-
ning, most patients suffered from prolonged and delayed nausea
and vomiting (74% of the patients), which affected their daily
life quality. However, almost all patients with these symptoms
responded well to orally administered ondansetron and the rate
of nausea/vomiting decreased in the following days by the use of
ondansetron intravenously or orally.
Survival and Recurrence
The overall median survival in the whole cohort (n 
20) was 17.2 months (Figure 2). It was 19.6 and 23.9 months
in patients who underwent EPP (n  16) and who completed
the trimodality treatment (n  12), respectively. There was
no statistically significant difference (p  0.52).
In eight patients, extrapleural lymph node metastasis
was detected. The patients had metastasis at internal mam-
mary (n  3), subcarinal (n 2), pulmonary ligament (n  1),
diaphragmatic and paraesophageal (n  1), and subaortic
(n  1) lymph nodes. The median survival was 13.3 months
in patients with extrapleural lymph node metastasis and 23.9
months in patients without lymph node metastasis (Figure 3).
This survival difference was very close to significance (p 
0.052). Two patients who had mixed histology and no lymph
node involvement died at 24 and 15 months because of chest
wall and intrathoracic recurrence. When these two patients
were excluded from the survival analysis, the median survival
was not reached in patients with epithelial histology and
without lymph node metastasis. Three-year survival rate was
56% (n  6).
Nine patients who underwent EPP recurred. Median time
to recurrence was 10 months (2–26). Five recurrences occurred
TABLE 1. Patient Characteristics
Gender
Male 12 (60)
Female 8 (40)
Exposure
Environmentala 16 (80)
Other 4 (20)
Diseased side
Right 11 (55)
Left 9 (45)
Histology
Epithelial 17 (85)
Mixed 2 (10)
Sarcomatoid 1 (5)
All values inside parentheses indicate percentages.
a Three patients had erionite exposure. Others had asbestos exposure.
FIGURE 2. Overall survival of the 20 patients who have
been included in the study. Median survival was 17.2
months.
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in patients with extrapleural lymph node involvement. The sites
were only peritoneum (n  2), peritoneum and local (n  1),
liver (n  1), and contralateral lung (n  1). Four patients
recurred in patients with no lymph node involvement and 2 of
these patients had mixed histology. The other two patients had
local and peritoneal (n  1) and solitary chest wall recurrence
(n  1). Chest wall recurrence occurred at the previous needle
puncture site, despite high-dose hemithoracic irradiation. The
lesion was excised and additional radiation was administered.
He is currently alive without recurrence at 21 months.
DISCUSSION
Several modifications of multimodal treatment modalities
have been investigated in the management of MPM. Reasonable
success was achieved with several versions of multimodality
treatment that included EPP, radiotherapy and/or chemotherapy
(Table 2).1–3,5,10–12 However, almost all of the patients with
MPM eventually recur in the chest, abdomen, or elsewhere.
Prophylactic radiation is recommended to puncture or incision
sites in all of the MPM patients.13
Aggressive surgery and radiation combination has proved
to be successful in local control of MPM.2,3,6,8,14 Especially after
removal of the lung with EPP, higher doses of radiation can be
administered to the hemithorax without any remaining lung
tissue. In a study from Memorial Sloan Kettering Cancer center,
local recurrence rate following EPP and high-dose hemithoracic
irradiation was less than 10% with most of the patients dying of
distant metastatic disease.2 In the same study, median survival of
34 months was achieved in early stage patients with EPP and
high-dose hemithoracic irradiation. IMRT also resulted in su-
perb early local control (100%) of the disease at clinical target
volumes of 45 to 50 Gy with boosts taken to 60 Gy.7 In our
study, 5 (31%, 5 of 16) local recurrences occurred following
EPP. However, our follow up was longer (16 months, 1–44),
compared with the study that instituted intensity modulated
radiation treatment (9 months, 5–27). Additionally, two of the
local recurrences occurred in patients with mixed histology. Our
radiation protocol was identical with the Memorial Sloan Ket-
tering Cancer center protocol.8
Intensification of radiation plays critical role in the mul-
timodality treatment of malignant mesothelioma for increasing
local control after EPP.8 Delivering high doses to the hemithorax
after surgery is challenging as the target volume, which is the
entire hemithorax including the mediastinum and all pleural
surfaces, are very close to critical organs such as liver, kidney,
heart, spinal cord, and remaining lung and they could easily be
affected from high-dose radiation. The use of combined photon
and electron fields to deliver a total dose of 54 Gy is a conve-
nient technique with adequate doses to these normal organs.
There have been some studies looking for the benefits of more
homogeneous dose distribution with IMRT after EPP to the
hemithorax.15 Although they have good local controls, the rate
of pneumonitis was more than conventional or so what we call
the MSKCC technique.8 In this study, we have applied this
technique with comparable local controls and toxicities.
Involvement of extrapleural lymph nodes was also shown
to be a poor prognostic factor in several studies.1,16,17 Some
TABLE 2. Survival of Patients Who Underwent Extrapleural Pneumonectomy (EPP)
and Multimodality Treatment for MPM
Author
No. of
Patients Multimodality Treatment
Overall Median
Survival (mo)
Median Survival
in Patients without
LN Metastasis (mo)
Sugarbaker et al.1 183 EPP  RT  CH 19 21
Rusch et al.2 62 EPP  HDRT NS 34
Flores et al.5 208 EPP  RT  CH 20 NS
Stewart et al.9 132 EPP  RT  CH 17 NS
Weder et al.10 45 CH  EPP  RT 23 NS
Rea et al.3 17 CH  EPP  HDRT 26 NS
de Perrot et al.11 50 EPP  RT 11 29
Batirel et al.a 16 EPP  HDRT  CH 20 24
MPM, malignant pleural mesothelioma; LN, lymph node; CH, chemotherapy; RT, radiotherapy; NS, not stated;
HDRT, high-dose radiotherapy.
a Current study.
FIGURE 3. Survival curves of patients with and without ex-
trapleural lymph node metastasis. The median survival of
patients with lymph node metastasis was 13.3 months. Pa-
tients without lymph node metastasis had a median survival
of 23.9 months (p  0.052).
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centers advocate routine cervical mediastinoscopy in the preop-
erative evaluation of MPM.18 However, in our patients, meta-
static lymph nodes were at inaccessible stations in more than
half of the patients (5 of 8). Our finding was observed by other
researchers, as 49% of mediastinal lymph nodes were inacces-
sible with cervical mediastinoscopy in a study from Leicester17
and similar results were found in the Toronto study.12 Two of
our 3 patients with internal mammary lymph node metastasis
recurred in the peritoneum and abdominal wall, which may
suggest a common lymphatic drainage and spread to the anterior
abdominal wall and peritoneum other than direct peritoneal
seeding during surgery. All of our patients with internal mam-
mary lymph node metastasis were from the famous Karain
village in Central Anatolia and MPM were due to erionite
exposure. Overall, five of our patients recurred in the abdomen
and it is an important issue in the long-term survival of these
patients.18
Our study was a phase II protocol to test the applica-
bility of this treatment protocol. Our relatively long follow-up
also allows us to make conclusions regarding the impact of
the protocol to overall survival. Our survival figure of 23.9
months in patients who completed trimodality treatment is
concordant with the literature data. The outcome in patients
(56% 3-year survival) without lymph node metastasis is
highly supportive of a multimodality approach as the standard
treatment in this subgroup of patients. Additionally, the
benefit of adjuvant chemotherapy seems to be in patients with
extrapleural lymph node metastasis. Our survival rate of 13.3
months (1–32) in this patient group seems to be longer than
that is reported in the literature (9 months).1,19
Currently, we perform PET scans to all of our patients to
assess extrapleural lymph node metastasis. Unfortunately, there
is not enough data regarding the accuracy of PET for this task
and it failed to correctly identify extrapleural lymph node me-
tastasis in the initial studies.20,21 All of the invasive mediastinal
staging procedures should be performed, if there is any suspicion
of lymph node involvement. Neoadjuvant chemotherapy can be
considered as a treatment option if there are any positive ex-
trapleural lymph nodes.6,11,22 The median survivals are promis-
ing in Weder (23 months) and Flores (34 months) studies
following EPP after neoadjuvant chemotherapy.6,11
There are several obstacles in performing our protocol,
which is typical of such protocols. First, the treatment is very
difficult for the patient and it usually takes about 4 to 6
months to complete the trimodality regimen if the postoper-
ative course is uneventful. In our series, 75% (12 of 16) of
patients who underwent EPP could complete the trimodality
protocol. Of the 4 patients who could not complete the protocol,
3 patients had postoperative complications and 1 patient with
multiple metastatic lymph nodes and aggressive histology (dif-
fuse intratumoral vascular and lymphatic invasion) recurring at
3 months in the abdomen. Second, the chemotherapy regimens
are not standard. The typical regimens were three cycles of
pemetrexed-cisplatin or gemcitabine-cisplatin. Most of the pa-
tients received their treatments at their home towns.
In conclusion, our study shows that trimodality treat-
ment consisting of aggressive surgery and adjuvant high-dose
irradiation and chemotherapy can achieve significantly long
survival times in patients without extrapleural lymph node
involvement. Although the number of patients treated with
this protocol is limited, this is a prospective patient series that
includes patients treated with relatively newer chemothera-
peutic agents. Our survival results are similar to other ver-
sions of multimodality treatment options. It is well tolerated
by the patients (75% completion in patients who underwent
EPP) and local and distant recurrence rates are low. However,
the benefit of this treatment in patients with extrapleural
lymph node involvement is questionable. Better extrapleural
lymph node staging methods are needed to stratify patients
who will benefit most from trimodality approach.
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